title: A multicentre study of vigabatrin for drug-resistant epilepsy.
abstract: 1. Vigabatrin (GVG) was given in a single-blind fashion to 89 patients with complex partial seizures (CPS) refractory to conventional drugs. 2. The median number of CPS per month decreased from 11.0 to 5.0 after addition of GVG, and 51% of patients had a 50% or greater decrease in CPS frequency (P less than 0.001). 3. Side effects (principally drowsiness, ataxia, headache) occurred mainly during the initiation of therapy and decreased during therapy. After 12 weeks on GVG side effects significantly interfered with functioning in only 13% of patients, and the efficacy: toxicity ratio warranted continued administration in 74% of patients. 4. Co-administration of GVG resulted in a mean decrease of 20% in phenytoin serum concentration (P less than 0.001). 5. Sixty-six patients having a favourable response to GVG during the single-blind study have been followed for 6-54 (median 33) months on GVG. Only 17 patients have dropped out of long-term follow-up due to break through seizures and/or side effects. No serious systemic or neurological toxicity has been detected.
authors.affiliation: Department of Neurology, Veterans Administration Medical Center, Boston, MA 02130.
authors.forename: T R
authors.initials: TR
authors.lastname: Browne
authors.forename: R H
authors.initials: RH
authors.lastname: Mattson
authors.forename: J K
authors.initials: JK
authors.lastname: Penry
authors.forename: D B
authors.initials: DB
authors.lastname: Smith
authors.forename: D M
authors.initials: DM
authors.lastname: Treiman
authors.forename: B J
authors.initials: BJ
authors.lastname: Wilder
authors.forename: E
authors.initials: E
authors.lastname: Ben-Menachem
authors.forename: R M
authors.initials: RM
authors.lastname: Miketta
authors.forename: K M
authors.initials: KM
authors.lastname: Sherry
authors.forename: G K
authors.initials: GK
authors.lastname: Szabo
mesh_terms: D000328:Adult; D000368:Aged; D000614:Aminocaproates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D004827:Epilepsy / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D010672:Phenytoin / Q000097:blood; D020888:Vigabatrin
chemical_list: D000614:Aminocaproates; D000927:Anticonvulsants; D010672:Phenytoin; D020888:Vigabatrin